Baseline estimated renal function was normal (eGFR 90 mL/min/1.73m 2 ) in 63.1%, mildly impaired (eGFR 60 to 90 mL/min/1.73m 2 ) in 34.3%, and moderately impaired (eGFR 30 to 60 mL/min/1.73m 2 ) in 2.5% of the patients
Large studies show significant average weight loss and improvements in cardiometabolic risk factors with semaglutide and related agents
The standard protocol begins with a 0.25 mg starting dose administered once weekly, then advances to 0.5 mg in week five, followed by 1.0 mg in week nine, and potentially reaching 2.0 mg or higher by week thirteen depending on individual tolerance
However, in some cases, they can mildly increase medication concentration and exposure
A deep dive into public Facebook posts uncovers the real-world side effect patterns of GLP-1 medications, revealing what users actually experience outside of clinical trials